Advanced Solid Tumor Malignancies

Trial Name: BGB-A1217/BGB-A317 Phase 1/1b Study Investigating Safety, Tolerability,
Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors

People with Advanced Solid Tumor Malignancies are asked to participate in a research study being conducted by Montefiore Medical Center.

You may be eligible to participate in this study if you:
• Are a male or female at least 18 years of age
• Have histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors
• Have adequate organ function
• Have histologically or cytologically confirmed extensive-stage SCLC with no prior systemic therapy
• Have archived tumor tissue or fresh biopsy

You may NOT participate in this study if you:
• Have active leptomeningeal disease or uncontrolled brain metastasis
• Have any active malignancy
• Have history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases
• Have known immunodeficiency virus (HIV) infection, hepatitis B or C
• Had major surgery (<3 weeks prior to the first dose of study drugs) • Are pregnant or breastfeeding Contact Information Cristal Garcia, Study Coordinator 1695 Eastchester Road – Bronx, NY 10461 Phone: (718) 405-8477 Fax: (718) 405-8230 Email: